ArticleHuman vaccines & immunotherapeutics2024

Post-marketing safety surveillance study of a 9-valent human papillomavirus vaccine: Comment.

Hinpetch Daungsupawong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.